NEW YORK, March 28, 2011 /PRNewswire/ — Keryx
Biopharmaceuticals, Inc. (Nasdaq:
KERX) (the “Company”) today announced that two abstracts on
KRX-0401 (perifosine) will be presented at the upcoming 102nd
annual meeting of the American Association for Cancer Research
(AACR) to be held in Orlando, Florida, from April 2-6, 2011.
Perifosine, the Company’s novel, potentially first-in-class, oral
anti-cancer agent that inhibits Akt activation in the
phosphoinositide 3-kinase (PI3K) pathway, is currently in Phase 3
clinical trials for refractory advanced colorectal cancer and
multiple myeloma. Both of these Phase 3 programs are being
conducted under Special Protocol Assessment (SPA) agreements with
the FDA, and with Fast Track designations obtained for both
indications. Perifosine is also in Phase 1 and 2 clinical
development for several other tumor
types.Sunday, April 3, 2011Abstract #640:
“The Akt inhibitor Perifosine strongly enhances the antitumor
and antivascular activity of CD34+ cells engineered to express
membrane-bound tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL)”, A. Giacomini, S. L. Locatelli, M. Righi, L.
Cleris, P.D. Longoni, M. Milanesi, M. Francolini, M. Magni, M. Di
Nicola, A. M. Gianni, C. Carlo-Stella.Date and time:
Sunday, April 3, 2011, 1:00-5:00 p.m. Eastern (Exhibit Hall
A4-C)Poster Session ID:
Cellular and Molecular Biology 27Poster Section:
27 Poster Board:
14Monday, April 4, 2011Abstract #1965:
“Antitumor activity of novel Akt inhibitor, perifosine in
gastric cell lines.”, Tae Soo Kim, Hyo Song Kim, Bo Ram Kwan,
Chan Hee Park Park, Hei-Cheul Jeung Jeung, Woo Ick Jang, Juergen
Engel, Hyun Cheol Chung, Jae Kyung Roh, Sun Young Rha.Date and
time:
Monday, April 4, 2011, 1:00-5:00 p.m. Eastern (Exhibit Hall
A4-C)Poster Session ID:
‘/>”/>
SOURCE
